²²⁵Ac-DOTAZOL is a DOTA Zoledronic acid derivative suitable for alphatherapy in complement to ¹⁷⁷Lu-Radiotherapy. ²²⁵Ac-DOTAZOL is a potent bisphosphonate for alpharadiotherapy of bone diseases tested in prostate cancer patients.

The first preclinical data were published in 2018. ²²⁵Ac-DOTAZOL confirms the well-known pharmacology of DOTAZOL derivatives (⁶⁸Ga and ¹⁷⁷Lu) in preclinical evaluations.

Target/Mechanism: Bones

Carrier/Ligand: n/a

Radiation Type: Alpha particle (α)